Truist Securities Maintains Buy on Carlsmed, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 61.5%

Neg 61.5% Neu 0% Pos 0%

Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and lowers the price target from $20 to $18.